Anzeige
Meldung des Tages: Wegweisende News: NurExone – Pionier der regenerativen neuronalen Medizin!

OKYO PHARMA LTD News

Aktie
WKN:  A2JQ3D ISIN:  GG00BD3FV870 US-Symbol:  EMMLF
Keine aktuellen Kursdaten verfügbar
Depot/Watchlist
Dieses Wertpapier ist nicht mehr handelbar.
Marktkapitalisierung *
-
Streubesitz
68,08%
KGV
-
Index-Zuordnung
-

OKYO PHARMA LTD News

23.02.26 - GlobeNewswire
OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress
LONDON and NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-​stage biopharmaceutical company developing investigational ...
13.02.26 - GlobeNewswire
OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares
LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-​stage biopharmaceutical company developing investigational ...
12.02.26 - GlobeNewswire
OKYO Pharma Announces Public Offering of Ordinary Shares
LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq:  OKYO ), a clinical-​stage biopharmaceutical company developing investigational ...
11.02.26 - GlobeNewswire
OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners
LONDON and NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq:  OKYO ), a clinical-​stage biopharmaceutical company developing investigational ...
10.02.26 - GlobeNewswire
OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer
Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in ...
30.01.26 - GlobeNewswire
OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting
LONDON and NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-​stage biopharmaceutical company developing investigational ...
28.01.26 - GlobeNewswire
OKYO Pharma Announces Successful Type C Meeting with the FDA
FDA confirms Phase 2b/3 clinical design, including primary endpoint, sample size and development approach
23.01.26 - GlobeNewswire
FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain
LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq:  OKYO ), a clinical-​stage biopharmaceutical company developing investigational ...
05.01.26 - GlobeNewswire
OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer
Accomplished industry leader Robert J. Dempsey brings extensive commercialization and ophthalmic expertise Gary S. Jacob, Ph.D., will transition to Chief Development Officer ...
19.12.25 - GlobeNewswire
OKYO Pharma to Ring the Opening Bell at Nasdaq
LONDON and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), a clinical-​stage biopharmaceutical company which is developing ...
15.12.25 - GlobeNewswire
OKYO Pharma Announces Chairman and Founder Acquires Shares
LONDON and NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:  OKYO ), an ophthalmology-​focused bio-​pharmaceutical company which is ...
11.12.25 - GlobeNewswire
OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain
Patients treated with 0.05% urcosimod demonstrated directionally favorable improvements in nerve fiber count and fiber length, trends not observed in the placebo group These ...
03.12.25 - GlobeNewswire
OKYO Pharma Announces Chairman and Founder Acquires Shares
LONDON and NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), an ophthalmology-​focused bio-​pharmaceutical company which is ...
21.11.25 - GlobeNewswire
OKYO Pharma Announces Chairman and Founder Acquires Shares
LONDON and NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:  OKYO ), an ophthalmology-​focused bio-​pharmaceutical company which is ...
18.11.25 - GlobeNewswire
OKYO Pharma to Present at OIS XV in San Diego
LONDON and NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:  OKYO ), an ophthalmology-​focused bio-​pharmaceutical company which is ...
29.10.25 - GlobeNewswire
OKYO Pharma to Present at BIO-Europe 2025 in Vienna
LONDON and NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:  OKYO ), a clinical-​stage biopharmaceutical company developing innovative ...
16.10.25 - GlobeNewswire
OKYO Pharma Announces Chairman and Founder Acquires Shares
LONDON and NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:  OKYO ), an ophthalmology-​focused bio-​pharmaceutical company which is ...
22.09.25 - GlobeNewswire
OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain
LONDON and NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), an ophthalmology-​focused bio-​pharmaceutical company which is ...
17.07.25 - GlobeNewswire
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain
LONDON and NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), an ophthalmology-​focused bio-​pharmaceutical company which is ...
16.07.25 - GlobeNewswire
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain
After 12 weeks of treatment, 75% of per-​protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neuropathic corneal pain (NCP), as measured by Visual ...

Newssuche

Videos

newspaper
25.02.26
So beeinflussen Margins DEIN Trading
Börsentäglich ab 18 Uhr Feierabend-​Trading Live. Teilnahme kostenlos mit diesem Link ... Mehr »